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 The existing body of literature focuses on the onset of panic disorders or other side 
effects as an association with cannabis use, but does little to address how possible concomitant 
cannabis use affects symptom presentation in already-diagnosed patients. The present project 
aims to take a closer look at adults with a lifetime history of DSM-5 diagnosed anxiety disorders, 
their prescribed (non-cannabis) medication use, cannabis use frequency, and associated symptom 
severity.  
 In general, we find that cannabis use is associated with higher panic-anxiety symptom 
severity across panic disorder without agoraphobia, generalized anxiety disorder, and people 
with combined anxious-distress diagnoses, after controlling for prescription medication status 
and professional help seeking. However, the difference between users and non-users is often 
small and not necessarily clinically relevant: only 1 or 2 symptoms. Worth noting is that we 
found no dose-response relationship for frequency of cannabis use. Being an infrequent user is 
not significantly different than being a daily user in terms of unique symptom presentation. This 
means that increasingly higher cannabis use does not necessarily induce increasingly more 
severe anxiety or distress. Rather, it seems that once an individual’s cannabis use crosses over a 
certain threshold, symptom presentation increases. For some disorders, this is an all-or-none 
phenomenon; any cannabis use is associated with more severe symptoms than staying abstinent. 
For others, only daily users present with higher symptoms than non-users. The sole divergence to 
this conclusion is that panic without agoraphobia patients who use infrequently seem to have 
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Total N (%)* 
Cannabis use within the 
last 12 months      
No 1215 (83.85) 284 (78.45) 1024 (81.59) 2285 (84.38) 3948 (84.20) 
Yes 234 (16.15) 78 (21.55) 230 (18.33) 420 (15.51) 737 (15.72) 




















for the affected anxiety 
disorder      
No 608 (41.90) 70 (19.34) 852 (67.89) 2040 (75.33) 2480 (52.89) 
Yes 838 (57.75) 290 (80.11) 400 (31.87) 666 (24.59) 2191 (46.73) 
Sought help from a private 
physician, psychiatrist, 
psychologist, social 














Race/ethnicity      
     White 962 (66.30) 247 (68.23) 863 (68.76) 1794 (66.25) 3091 (65.92) 
     Black 208 (14.33) 48 (13.26) 151 (12.03) 413 (15.25) 697 (14.86) 
     American Indian     
    /Alaska Native 41 (2.83) 16 (4.42) 35 (2.79) 58 (2.14) 107 (2.28) 
     Asian/ Pacific Islander 25 (1.72) 3 (0.83) 20 (1.59) 75 (2.77) 111 (2.37) 
     Hispanic (any race) 215 (14.82) 48 (13.26) 186 (14.82) 368 (13.59) 683 (14.57) 
Age (years), mean ± SD 43.63±14.56 42.20±13.85 44.04±16.60 47.09±15.54 45.72± 15.93 
Age (years) at first use of 
marijuana, mean ± SD 16.76±5.43 16.04±4.33 16.98±5.45 17.63±5.53 17.40±6.41 
Sex      
     Female 1042 (71.81) 277 (76.52) 801 (63.82) 1836 (67.80) 3186 (67.95) 
     Male 409 (28.19) 85 (23.48) 454 (36.18) 872 (32.20) 1503 (32.05) 
Education      
     Less than high school 212 (14.61) 58 (16.02) 191 (15.22) 346 (12.78) 661 (14.10) 
     High school graduate 375 (25.84) 104 (28.73) 378 (30.12) 673 (24.85) 1211 (25.83) 
     At least some college 
up to a Bachelor’s 703 (48.45) 166 (45.86) 572 (45.58) 1279 (47.23) 2220 (47.34) 
At least some graduate 
studies 161 (11.10) 34 (9.39) 114 (9.08) 410 (15.14) 597 (12.73) 
Marital status      
     Never married 341 (23.50) 103 (28.45) 374 (29.80) 625 (23.08) 1167 (24.89) 
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     Married or living with 
someone as if married 620 (42.73) 150 (41.44) 511 (40.72) 1149 (42.43) 1983 (42.29) 
     Widowed 86 (5.93) 17 (4.70) 86 (6.85) 226 (8.35) 354 (7.55) 
     Separated or divorced 404 (27.84) 92 (25.41) 284 (22.63) 708 (26.14) 1185 (25.27) 
Number of comorbidities      
     1 935 (64.44) 125 (34.53) 619 (49.32) 1820 (67.21) 3499 (74.62) 
     2 407 (28.05) 137 (37.85) 427 (34.02) 679 (25.07) 825 (17.59) 
     3  109 (7.51) 100 (27.62) 209 (16.65) 209 (7.72) 209 (4.46) 
      
*may not add up to 100% due to some missing values or overlap in multiple comorbidities. Also, 
panic disorder alone and panic disorder with agoraphobia are mutually exclusive diagnoses. 
 
Table 2. Unadjusted association between cannabis use frequency and symptom severity category 
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Table 3. Unadjusted ordinal logistic regression model for association between cannabis use 
frequency and increasing levels of symptom severity (zero-mild, moderate, high and severe) 
Disorder Variable OR (95% CI) p 
Panic Disorder Cannabis use frequency 
No use 
Monthly or weekly 
Daily or near daily 
 
1.00 
1.508 (1.011, 2.248) 





Panic Disorder with 
Agoraphobia 
Cannabis use frequency 
No use 
Monthly or weekly 
Daily or near daily 
 
1.00 
1.515 (0.844, 2.719)  







Cannabis use frequency 
No use 
Monthly or weekly 
Daily or near daily 
1.00 
1.359 (0.884, 2.090) 






Cannabis use frequency 
No use 
Monthly or weekly 
Daily or near daily 
1.00 
1.450 (1.072, 1.961) 





Symptoms, a group 
that comprises of 
patients with at 








anxiety disorder  
Cannabis use frequency 
No use 
Monthly or weekly 
Daily or near daily 
 
1.00 
1.488 (1.194, 1.855) 










Table 4. Adjusted ordinal logistic regression model for relationship between cannabis use 
frequency and increasing symptom severity categories (zero/none, low, moderate, and severe) 
Disorder Variable* OR (95% CI) p 
Panic Disorder Cannabis use frequency 
No use 
Monthly or weekly 
Daily or near daily 




Sought help from a private 
physician, psychiatrist, 
psychologist, social worker, or 






1.449 (0.977, 2.150) 

































Less than high school 
High school or equivalent 
At least some college 
At least some graduate school 
1.00 
1.656 (1.143, 2.399) 
1.198 (0.458, 3.136) 
1.035 (0.509, 2.105) 
1.567 (1.087, 2.258 ) 
1.504 (1.058, 2.138) 
 
1.00 
0.927 (0.594, 1.446) 
0.731 (0.455, 1.173) 












Panic Disorder with 
Agoraphobia 
Cannabis use frequency 
No use 
Monthly or weekly 
Daily or near daily 






1.063 (0.541, 2.086) 













 Sought help from a private 
physician, psychiatrist, 
psychologist, social worker, or 


















2.716 (1.332, 5.539) 









3.588 (1.259, 10.231) 




Less than high school 
High school or equivalent 
At least some college 
At least some graduate school 
 
1.00 
0.649 (0.343, 1.229) 
0.449 (0.236, 0.853) 








Cannabis use frequency 
No use 
Monthly or weekly 
Daily or near daily 
1.00 
1.317 (0.853, 2.031)  









2.269 (1.626, 3.165) 
--- 
<.0001 
 Sought help from a private 
physician, psychiatrist, 
psychologist, social worker, or 
















Less than high school 
High school or equivalent 
At least some college 
At least some graduate school 
1.00 
0.799 (0.465, 1.372) 
0.604 (0.401, 0.909) 







Cannabis use frequency 
No use 
Monthly or weekly 
Daily or near daily 
1.00 
1.218 (0.898, 1.653) 
















 Sought help from a private 
physician, psychiatrist, 
psychologist, social worker, or 




2.543 (1.889, 3.422) 
--- 
<.0001 
 Age 0.982 (0.976, 0.988) <.0001 
 Education 
Less than high school 
High school or equivalent 
At least some college 
1.00 
1.103 (0.839, 1.450) 
0.771 (0.608, 0.978) 







At least some graduate school 
Anxious-Distress 
Symptoms, a group 
that comprises of 
patients with at 








anxiety disorder  
Cannabis use frequency 
No use 
Monthly or weekly 
Daily or near daily 
 
1.00 
1.297 (1.022, 1.645) 

















 Sought help from a private 
physician, psychiatrist, 
psychologist, social worker, or 















1.193 (0.972, 1.464) 
1.642 (1.095, 2.461) 
1.432 (1.017, 2.017) 


















Less than high school 
High school or equivalent 
At least some college 
At least some graduate school 
1.00 
1.026 (0.824, 1.279) 
0.714 (0.571, 0.894) 





    
*controlling variables were omitted from the final model via backwards selection if they did not 





Table 5. Unadjusted multiple linear regression model for relationship between ln(past year 
symptom count) and cannabis use frequency 
Disorder Variable Adjusted β (SE) p 
Panic Disorder Cannabis use frequency 
No use 
Monthly or weekly 









Panic Disorder with 
Agoraphobia 
Cannabis use frequency 
No use 
Monthly or weekly 
Daily or near daily 
 
Reference 








Cannabis use frequency 
No use 
Monthly or weekly 









Cannabis use frequency 
No use 
Monthly or weekly 








Symptoms, a group 
that comprises of 
patients with at 








anxiety disorder  
Cannabis use frequency 
No use 
Monthly or weekly 














Table 6. Adjusted multiple linear regression model for relationship between ln(past year 
symptom count) and cannabis use frequency (N= 4689) 
Disorder Variable Adjusted β (SE) p 
Panic Disorder Cannabis use frequency 
No use 
Monthly or weekly 
Daily or near daily 




Sought help from a private 
physician, psychiatrist, 







0.051 (0.025)  

































Less than high school 
High school or equivalent 
At least some college 

























Cannabis use frequency 
No use 
Monthly or weekly 
Daily or near daily 


































Less than high school 









At least some college 
At least some graduate school 
-0.180 (0.047) 0.0002 
Social Anxiety 
Disorder 
Cannabis use frequency 
No use 
Monthly or weekly 














 Sought help from a private 
physician, psychiatrist, 

















Less than high school 
High school or equivalent 
At least some college 











Cannabis use frequency 
No use 
Monthly or weekly 















 Sought help from a private 
physician, psychiatrist, 



























Less than high school 
High school or equivalent 
At least some college 















patients with at 








anxiety disorder  
Cannabis use frequency 
No use 
Monthly or weekly 

















 Sought help from a private 
physician, psychiatrist, 


























 Age -0.004 (0.001) <.0001 
 Education 
Less than high school 
High school or equivalent 
At least some college 











    
*controlling variables were omitted from the final model via backwards selection if they did not 




BACKGROUND & RATIONALE   
 Self-medication for existing anxiety and mood disorders is quite common in adults 
(Bolton 2009). Cannabis is a popular drug of choice for relief from a variety of conditions 
including migraines, everyday stresses and sleeping difficulties resulting from insomnia as well 
as both disordered and non-disordered or “common” anxiety (Ogborne 2000; Bonn-Miller et al., 
2007; Buckner et al., 2008). According to a review by Wittchen et. al. (2007), a number of 
prospective studies have shown that the presence of highly symptomatic anxiety disorders in 
adolescence significantly predicts cannabis use later in adulthood. 
 While people report reduced anxiety as their primary motivation for using cannabis, 
paradoxically, acute anxiety is the most common adverse effect of cannabis use. When taken in 
high doses, [(>5 mg oralD9-tetrahydrocannabinol (D9-THC) for a man of average weight], 
cannabis can cause intense  fear, anxiety, panic and phobic attacks (Hall and Solowij, 1998; 
Thomas, 1993; Tournier et al., 2003). This conflict in evidence may be mediated by the 
observation that the side effects of cannabis appear to be dose-dependent. For example, low 
doses of the cannabinoid receptor agonists, nabilone (Onaivi et al., 1990) and D9-THC 
(Berrendero and Maldonado, 2002) have anxiolytic-like effects in laboratory rodents, whereas 
higher doses produce anxiogenic behaviour and activate the hypotalamic–pituitary–
adrenocortical axis (Berren-dero and Maldonado, 2002; Giuliani et al., 2000; Viveros et al., 
2005). This necessitates a closer look at the potential therapeutic effects of cannabis self-
medication through the lens of frequency and dose of use.  
 Furthermore, the existing body of literature seems to focus on the onset of panic disorders 
or other side effects as an association with cannabis use, but does little to address how possible 
concomitant cannabis use affects symptom presentation in already-diagnosed patients. There is 
currently little known about how cannabis interacts with prescription medication in symptom 
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abation. The present project aims to take a closer look at adults with a history of DSM-5 
diagnosed panic, social anxiety, or generalized anxiety disorder, their prescribed (non-cannabis) 
medication use, cannabis use status, and associated symptom severity. For example: does self-
medication with cannabis in lieu of prescribed medication abate symptoms? If a person is already 
taking anxiety medication, does simultaneously using cannabis have even greater symptom 
reduction than using prescriptions alone? Or does it have no additional benefit? We are hoping to 
compare symptom presentation of groups of people based on cannabis use status while 
controlling for prescribed medication status. Additionally, we investigate the plausibility of a 





 The National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-
III) was sponsored, designed and directed by the National Institute on Alcohol Abuse and 
Alcoholism (NIAAA). The NESARC-III is cross-sectional, based on a nationally representative 
sample of the civilian population of the United States. 
 The NESARC-III contains data from a well-characterized population sample, containing 
demographic data as well as various information such as lifetime and past 12 month history of 
chronic diseases/disorders/disabilities, substance use attitudes, and self-reports of symptoms. 
Data on cannabis use and frequency is available for both lifetime and past year use.  Particular 
focus will be put on patients who have current (within the past year) active diagnoses and their 
current symptoms, as their experiences may be more salient and more accurately reported while 
completing the NESARC-3 survey. All patients are non-institutionalized adults ages 18 years 
and over residing in the US.  
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 Full survey methodology can be found on the NIH website. 
 
Study Population 
 In total, 36,309 adults were captured with the NESARC-III survey. In this study, I 
focused on 4,689 individuals who had a lifetime history of  DSM-5 diagnosed anxiety-related  
disorders, including panic disorder without agoraphobia (n= 1451), panic disorder with 
agoraphobia (n=362),  social anxiety disorder (n=1255), and generalized anxiety disorder (n= 
2708) in the US. Of this anxiety-related subset, 825 individuals had a lifetime history of 2 or 





 Cannabis Use. The primary independent variable of interest is current (defined as past-
year) use of cannabis. Past year cannabis use was assessed by the NESARC-III questions that ask 
“Have you ever used cannabis?” and if so, “Have you used cannabis within the last 12 months?”. 
Based off of these questions, past year cannabis use is coded as “Yes”, “No”, or “Missing”. 
 A variable for cannabis use frequency was also derived from a NESARC-III question that 
asked, “How often do you use cannabis?”. The original question had 13 response levels, ranging 
from never to daily. We chose to collapse these levels into 3: never, monthly or weekly, daily or 
more days than not. The reasoning behind these new categorizations is that 1.) a large proportion 
of people choose not to use cannabis or choose not to reveal their usage out of stigma and 2.) 
daily or near daily users may have an additional motive for cannabis usage, implying that they 
are more likely to be using it as a coping mechanism or self-medication, whereas recreational 
users likely are not reliant on continuous use for symptom management. 
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 Medication status. The medication status variable reflects whether or not a patient has 
ever been prescribed medication for their specific panic-anxiety disorder by a physician. 
 Possible confounders. There remains a possibility that having more than 1 panic-anxiety 
disorder may non-linearly increase the magnitude of symptom presentation. To address this, we 
looked at comorbidity, creating a variable that captured how many conditions (1-3 out of panic 
disorder without agoraphobia, panic disorder with agoraphobia, social anxiety disorder, and 
general anxiety disorder) an individual met lifetime for. 
 Additionally, it is common practice for patients suffering from panic-anxiety symptoms 
to manage their symptoms with talk therapy with or without medication. Although the NESARC-
III survey does not specifically address psychotherapy in its probing for each disorder, we 
attempt to control for this by creating a variable that reflects whether or not a patient has sought 
help for their condition from a private physician, psychiatrist, psychologist, social worker, or any 
other professional. 
 Demographics. We included the following demographic variables: age, sex, race, marital 
status, and educational attainment. 
 Age was left as its original continuous variable. 
 Race was included as a categorical variable, with its levels being: White, Black, Native-
American, Asian, and Hispanic. 
 Marital status was collapsed from its original categorical variable, to include 4 levels: 
Never Married, Married/Common-Law Marriage, Separated/Divorced and Widowed. 
 Educational attainment was collapsed from its original 14 level variable into a 4 level 
ordinal categorical variable, categorized as less than high school, high school or equivalent, some 





 Symptom severity. Under a separate section for each disorder, the NESARC-III survey 
asks questions akin to “Do you have an intense fear of using public transportation?” and “Do you 
often feel detached from things around you?” in an effort to measure how symptomatic the 
respondents are during a specified time period. These questions are directly referenced from the 
DSM-5 diagnostic criteria for their respective disorders (American Psychiatric Association, 
2013). We define “current symptoms” as any symptom occurring within the past year (last 12 
months). First, within each disorder, for this time period, we tallied up the number of symptom 
questions to which patients responded “Yes”; “No” responses did not contribute to the count, and 
“Missing” responses were few enough in number to be safely excluded without fear of 
disproportionality or bias. This symptom count variable is treated as continuous when used for 
linear regression modeling (see “Data Analysis”). A composite version of this variable was 
created by simply summing up all symptom tallies for all disorders of interest; this all-
encompassing symptom severity variable is meant to allow us to assess symptom presentation 
for all patients within our panic-anxiety population, regardless of formal DSM-5 diagnosis. This 
is done to account for the fact that while an individual can be clinically diagnosed with one 
disorder, they may still experience some symptoms that are associated with another, to a lesser 
extent (e.g., someone with a generalized anxiety diagnosis can still experience panic attacks, but 
not to the magnitude that they would also meet panic disorder DSM-5 criteria).  
 Secondly, we converted our symptom count variables to reflect an ordinal categorization 
of severity for use in chi-square and ordinal logistic regression (see “Data Analysis”). The 
ordinal symptom severity variables all have 4 levels: none-mild, moderate, high, and severe 
20 
 
based on quartiles. The count distribution was divided into quartiles to populate the none-mild, 




 As part of exploratory analysis, unadjusted χ2 tests were performed for each disorder, as 
well as the entire sample of people who have any of the 4 disorders, looking for possible 
bivariate associations between symptom severity categories (zero/none, low, moderate, high and 
severe) and factors of interest. Bivariate analysis was also undertaken between symptom severity 
category and categorical demographic variables or other confounders. 
 
Ordinal Logistic Regression 
 Due to the ordinal nature of the symptom severity levels (i.e., zero/none, low, moderate, 
high and severe), we investigated the predictive power of cannabis use frequency and medication 
status via ordinal logistic regression. In addition, other possible predictor variables and possible 
confounders were added into the adjusted model. 
 
Multiple Linear Regression 
 We ensured that all symptom severity counts were normally distributed by transforming 
all of them into their natural logarithms. 
 The original symptom severity variables turned out to have counts high enough for them 
to be treated as continuous variables. Due to concerns that turning a continuous variable into a 
categorical one would abolish some of the nuance of the data, we decided to build both 






 I began by using descriptive statistics to summarize the characteristics of the sample, both 
overall and by disorder. Then, I started looking for possible bivariate associations between 
frequency of cannabis use and symptom severity for each disorder (as well as the whole anxious-
distress subset, for individuals who have a lifetime history of at least 1 of the 4 disorders of 
interest) using a chi square test.  
 Subsequently, I used two modeling approaches: 
 1.) For a 4-level ordinal outcome (the levels of symptom severity ranging from “none-
mild” to “severe”), I used ordinal logistic regression. Both the unadjusted and adjusted odds 
ratios and their respective 95% confidence intervals were calculated. Multivariable models 
adjusted for prescription medication status, whether or not an individual sought professional help 
within the last 12 months, age, gender, race, and educational status. 
 2.) For a continuous symptom score, I used linear regression. Given skewed, non-normal 
distributions for some of the disorder-specific scores, I transformed my symptoms scores to their 
natural logarithms. Again, multivariable models adjusted for prescription medication status, 
whether or not an individual sought professional help within the last 12 months, age, gender, race, 
and educational status. 
 All analyses were performed using SURVEY procedures in SAS to account for the 







 Overall, 15.72% of patients have used cannabis in some form during the last 12 months 
(see Table 1). Among the disorders, panic disorder with agoraphobia patients have the highest 
proportion of cannabis users, at 21.55%. 
 Across disorders, the proportions of people with a history of prescription medication use 
range from panic disorder with agoraphobia patients with the highest at 80.11% to generalized 
anxiety disorder patients with the lowest at 24.59%. 
 Additionally, the majority of our study population is female. Across all panic-anxiety 
disorders, 63.82% to 76.52% of patients are female. 
 Interestingly, people who are diagnosed with panic disorder with agoraphobia are more 
likely to also be diagnosed with the other disorders of interest (save panic disorder alone); 
27.62% of this patient group has a lifetime history of both social anxiety and generalized anxiety. 
 
χ2 test for association between cannabis use and symptom severity categories 
 Increasing frequency of cannabis use is associated with increasing symptom severity, 
although not statistically significant for panic disorder with agoraphobia and social anxiety 
disorder and marginally significant at p<0.10 for panic disorder without agoraphobia, 
generalized anxiety disorder, and the combined patient pool for all disorders of interest (see 
Table 2). 
 
Unadjusted ordinal logistic regression model for association between cannabis use 
frequency and increasing levels of symptom severity 
 Consistent with findings in Table 2, we find that increasing frequency of cannabis use is 
associated with increasing odds of more severity symptom level (p<.05) for all disorders except 
panic disorder with agoraphobia (see Table 3). However, we do see one discrepancy: now, social 
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anxiety patients who use cannabis on a daily or near daily basis have 1.808 times the odds of 
higher symptom presentation as people who are abstinent (p=0.0136). 
 
Adjusted ordinal logistic regression model for relationship between cannabis use frequency 
and increasing levels of symptom severity 
 There is no significant difference in the odds of being in a higher level of panic with 
agoraphobia, or social anxiety symptom severity between patients who use cannabis at any 
frequency and non-users (see Table 4; all p>(α=.05)). 
 GAD patients who use cannabis more days than not have higher odds of having a higher 
level of symptom severity than non-cannabis users, given that all of the other variables remain 
constant. Surprisingly, the same is not true for infrequent cannabis consumers; GAD patients 
who intake cannabis on weekly or monthly basis do not have a significantly different odds of 
higher symptom severity than non-users (p=0.2023). Similar results were found for panic 
disorder without agoraphobia patients, for which regular users have higher symptom severity 
(p=0.0341) compared to abstinent patients. Yet, infrequent cannabis users do not have 
significantly different odds of higher panic disorder severity (p=0.0648). 
 In an effort to look at anxiety-distress symptoms in general, non-specific to any disorder 
and not contingent on a person’s fulfillment of all of the DSM-5 criteria for diagnosis, we 
combined all of the disorders into one patient population. We found similar results in that a 
cannabis user of any frequency has increased anxious-distress symptom severity compared to 
non-users, given all of the other variables in the model are held constant (p< 0.0001).  
 There appear to be some confounding, complex underlying relationships between 
prescription medication status, age, race, and education that simultaneously account for 
differences in symptom severity. People have been prescribed medication and those who have 
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sought professional help for their disorder show increased symptom severity compared to those 
who did not. Consistent across all disorder-specific analyses, educational attainment seems to be 
a major contributor in particular. Beyond high school, people who have pursued higher 
education, be it in baccalaureate or graduate studies, have lower odds of presenting with higher 
levels or buckets of anxious-distress symptoms than non-high school graduates (all p<(α=.05)). 
Specifically, graduate students have the lowest odds of higher symptom severity.  
 The proportional odds assumption was not met for any of the ordinal logistic tests 
described above. The Score Tests for the Proportional Odds Assumption were highly significant, 
which indicates that the cumulative logit model might not adequately fit the data. In addition, 
concerns that categorizing the symptom presentation tallies (which have high enough counts to 
possibly be considered continuous) into arbitrary buckets might remove the nuance of patient 
responses prompted us to fit a multiple linear regression model. 
 
Unadjusted multiple linear regression model for relationship between past year symptom 
count and cannabis use frequency 
 Generally, we found a similar pattern of results found when symptom severity is modeled 
as a continuous outcome; increasing frequency of use is associated with higher symptom 
presentation (see Table 5). However, one major difference is that the added nuance has now 
allowed us to see a significant difference in symptom severity among all levels of cannabis use 
within the panic disorder without agoraphobia population. Additionally, panic disorder without 





Adjusted multiple linear regression model for relationship between past year symptom 
count and cannabis use frequency 
 In general, the adjusted model shows the same pattern of significance as the unadjusted 
model; higher frequency of cannabis use is associated with higher symptom presentation across 
all disorders except for social anxiety (see Table 6). This is seen most robustly for generalized 
anxiety disorder. 
 Pure panic disorder patients who partake in cannabis on a weekly or monthly basis have a 
5.2% more symptoms on average than those who are abstinent, holding all other variables 
constant (eβ =1.052). Unexpectedly, daily or near daily users do not have a significantly different 
mean symptom count than those who are abstinent. 
 In contrast, the exact opposite results for cannabis frequency levels hold true for patients 
who have a history of panic disorder with agoraphobia. 
 Similar results were found when we looked at our entire patient population as a whole, 
regardless of which of the 4 conditions of interest any individual was affected by. Those who 
consumed cannabis on a daily or nearly daily basis presented with 21.3% more symptoms on 
average compared to those who are abstinent (eβ =1.213) after controlling for confounders. 
Again, after adjustment, patients whose cannabis intake varies from once weekly or monthly had 
symptom severities that were on average 8.6% higher compared to non-cannabis users (eβ 
=1.06). 
 The importance of prescription medication status, seeking help from professionals, and 
educational attainment is evident. Not only are they significant predictors of symptom severity, 
but they also modulate cannabis use’s predictive value across all disorders. This is especially true 
in the case of social anxiety disorder, as all of cannabis use frequency’s effect on symptom count 
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has been mitigated after controlling for confounders. Sufferers of social anxiety do not have 
significantly different mean symptom counts, regardless of cannabis use frequency. 
 As for educational attainment, people who choose to pursue higher learning after high 
school, on average, have fewer anxious-distress symptoms than people who did not graduate 
from high school. 
 
DISCUSSION 
  In general, we find that cannabis use is associated with higher panic-anxiety symptom 
severity across panic disorder without agoraphobia, generalized anxiety disorder, and people 
with combined anxious-distress diagnoses after controlling for prescription medication status and 
professional help seeking. Worth noting is that we found no dose-response relationship for 
frequency of cannabis use. Being an infrequent user (defined as once monthly or weekly) is not 
significantly different than being a daily user in terms of unique symptom presentation. This 
means that increasingly higher cannabis use does not necessarily induce increasingly more 
severe anxiety or distress. Rather, it seems that once an individual’s cannabis use crosses over a 
certain threshold, symptom presentation increases. For some disorders, this is an all-or-none 
phenomenon; any cannabis use is associated with more severe symptoms than staying abstinent. 
For others, only daily users present with higher symptoms than non-users. The sole divergence to 
this conclusion is that panic without agoraphobia patients who use infrequently seem to have 
more severe symptoms than non-users and daily users. 
 Although cannabis is still registered as a Schedule 1 drug federally, a wave of state 
initiatives has decriminalized the drug in large swathes of the country, increasing the proportion 
of recreational users due to ease of access. Former restrictions limited the user pool to medicinal 
users to some degree, based on effectiveness of enforcement in certain regions. With the current 
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upswing of recreational marijuana legalization in the United States, new legislation will expand 
access to cannabis to a wider population. 
 This will usher in more widespread implications for public health, particularly because up 
to 33.7% of the population is affected by an anxiety disorder during their lifetime (Bandelow, 
2013). Panic disorder with or without agoraphobia, social anxiety disorder, and generalized 
anxiety disorder are the most prevalent anxiety disorders and are associated with immense health 
care costs. Due to the high burden of disease, many of these patients choose to self-medicate 
using cannabis. We found that cannabis use resonates with higher symptom presentation, 
regardless of frequency. However, we see from the parameter coefficients that the difference 
between users and non-users is often small and not necessarily clinically relevant: only 1 or 2 
symptoms.  Although this provides some insight if we define symptom severity as the number of 
unique symptom presentations, we should also consider the magnitude of impact these additional 
one or two symptoms may have on patients’ quality of life. For example, how life-changing is it 
if you develop sweaty palms? How about compared to developing excessive fear of social 
situations? However, barring the most extreme symptoms, cannabis use does not seem to cause 
excessive harm to the point of drastically reduced functioning. In fact, based off the distribution 
tables and the fact that more symptomatic patients are more likely to seek help or use 
prescription medication, it seems entirely possible that the same patients would try to self-
medicate using cannabis in an attempt to mitigate some of the more dehabilitating symptoms.  
 Contrary to current literature, age is not a major contributing factor for higher symptom 
presentation for any of the 4 anxiety disorders besides panic disorder, for which our patient 
population skews slightly young (Patton et. al., 2002). As cannabis policy reform moves forward, 
one of the greatest concerns legislators and parents have is that legalization will increase 
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cannabis use among young people, and in particular, initiate adolescent users who would not 
otherwise have used cannabis. In fact, even legal states such as Colorado and Massachusetts have 
an age threshold of 21 (down from previous restrictions of at least 25 years old for medical 
marijuana registration eligibility). However, the raison d’etre for this is rooted, in large part, in 
moralistic apprehensions rather than health-related ones. In addition to the null results seen in the 
present paper, regular cannabis use that begins in adolescence and continues throughout young 
adulthood appears to produce cognitive impairment but the mechanism and reversibility of the 
impairment is unclear (Hall, 2015).  
 As cannabis legislation becomes more permissive, either by lowering the age limit or 
expanding access, it is our hope that this will lift some of the restrictions on scientific 
investigations, allowing deeper clarity into the relationship between cannabis and health effects.  
Directions for future work include further comparisons of how anxious-distress symptoms 
severity presents in states with and without permissive cannabis legislation. Additionally, regular 
cannabis use has previously been associated with higher risks of developing chronic bronchitis, 
as well as higher risks of myocardial infarction in middle-aged adults (Hall, 2015). However, 
these effects may also be explained by tobacco use, for which cannabis use has long been 
difficult to disentangle from, as most smokers partake in both. Due to the incredibly varied 
methods of cannabis consumption (eg. extract vape, oils, regular flower), it may become possible 
to isolate or remove confounding factors (eg. minimize the confounding effect of physical 
combustion or smoke by studying only tobacco chewers and cannabis extract vapers). Given any 
health revelations that elucidate the health risks of cannabis relative to tobacco, this may in turn, 
allow us to revisit or revise tobacco laws when compared to cannabis laws and vice versa. 
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 A major limitation of this analysis lies in the cross-sectional nature of the NESARC-III 
survey. Patient responses are captured from a snapshot in time, rather than longitudinally. Of 
course, this means that a comparison of prior symptoms to current symptoms may be flawed, as 
prior symptoms are self-reported after possibly years of lag, resulting in memory bias. 
Additionally, this raises concerns about the actual chronological causality of effects from our 
“treatments”, medication status and cannabis use; how can we ascertain if more severe symptom 
presentation causes people to seek out medication or self-medicate with cannabis or if cannabis 
induces more severe symptoms? 
  Another potential pitfall is that within the survey definition of “cannabis use”, there is no 
differentiation between THC, which may be anxiety-inducing in high doses and CBD, which 
may be anxiolytic. This might confound some of the patient responses regarding anxiety 
symptoms. 
 Due to both the social stigma and possible legal ramifications of admitting to cannabis 
use in more conservative states, it is possible that our sample has underreported cannabis use. 
However, this bias is likely to only inflate the population of non-users and equally affect reported 
cannabis use across all other frequencies; social and legal ramifications usually do not 
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